Related Experiment Video
Updated: May 31, 2026
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
Published on: January 7, 2019
Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety
Lenard A Adler1, V Rose Lieberman2, Leslie Brijbasi2
1Department of Psychiatry, New York University Grossman School of Medicine, New York, New York.
Abstract:
Objective: Adult attention-deficit/hyperactivity disorder (ADHD) is commonly associated with comorbidities, including depression and anxiety; however, most ADHD treatment studies exclude people with these conditions. This phase 4, open-label, decentralized clinical trial (conducted March 25, 2024-December 11, 2024) evaluated viloxazine ER (extended-release capsules, an FDA-approved nonstimulant medication for ADHD) in adults with ADHD (based on DSM-5-TR) and comorbid depression and/or anxiety symptoms.
Abstract:
Methods: Participants received viloxazine ER (200-600 mg/d) for 14 weeks added to existing medications (including stimulant, antidepressant, or anxiolytic medications). Efficacy and safety measures (assessed via televisit, mobile phone app, and home monitoring devices) included clinician-and patient-reported scales evaluating ADHD, depression, and anxiety symptoms, treatment-emergent adverse events, blood pressure, pulse rate, weight, and suicidality assessment. The primary end point was change from baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS) total score.
Abstract:
Results: Among participants receiving viloxazine ER (n=161; mean age, 39.4 years; female, 75.8%), almost all (99.4%) had substantial depression and anxiety symptoms. AISRS total score was significantly reduced (improved) from baseline (mean [SD], 37.5 [6.53]; n=150) at week 14/end of study (EOS) (mean [SD] change, -17.3 [11.34]; P<.0001); similar results were observed for patient-reported ADHD symptoms. Depression and anxiety rating scales were significantly improved from baseline to week 14/EOS (all P<.0001). Safety outcomes were consistent with previous viloxazine ER studies; 24 participants (14.9%) had adverse events leading to study discontinuation.
Abstract:
Conclusions: Viloxazine ER was well tolerated and associated with improvements in ADHD, depression, and anxiety symptoms in this real-world study of adults with ADHD and comorbid symptoms.
Abstract:
Trial Registration: ClinicalTrials.gov identifier: NCT06185985.
Related Concept Videos
01:26Anxiolytic Drugs: Overview
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.
01:25Antidepressant Drugs: Overview
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:23Antidepressant Drugs: MAOIs and Other Agents
01:26Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone